Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Digestive System Neoplasms » Liver Neoplasms
Diseases [C] » Digestive System Diseases [C06] » Digestive System Neoplasms » Liver Neoplasms
Diseases [C] » Digestive System Diseases [C06] » Liver Diseases » Liver Neoplasms
Hierarchy View
Subtype Terms (3)
Adenoma, Liver Cell
2 drugs (1 approved, 1 experimental)
Carcinoma, Hepatocellular
659 drugs (209 approved, 450 experimental)
Liver Neoplasms, Experimental
2 drugs (1 approved, 1 experimental)
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (35)
Phase 3 Indicated Drugs (40)
Phase 1 Indicated Drugs (92)
autologous genetically modified afpc332 t cells
autologous hematopoietic stem cells
her2bi-armed activated t cells
hgm-csf herpes simplex virus injection
perflutren protein-type a microspheres (Optison)
prostate specific membrane antigen
recombinant adenoviral human p53 gene
recombinant fowlpox-cea(6d)/tricom vaccine
recombinant human il12/15-pdl1b oncolytic hsv-1 injection (vero cell))
Other Experimental Indicated Drugs (34)
Organization Involved with Phase 4 Indications (28)
Organization Involved with Phase 3 Indications (68)
Arbeitsgruppe Lebermetastasen und Tumoren
Centre Georges Francois Leclerc
Centre Hospital Universitaire Hop Huriez
Federation Francophone de Cancerologie Digestive
Medigen Biotechnology Corporation
Moorgreen Hospital, Southampton
Radiation Therapy Oncology Group
Organization Involved with Phase 2 Indications (167)
Aeon Therapeutics (Shanghai) Co., Ltd.
Assistance Publique - Hôpitaux de Paris
Association pour la Recherche sur le Temps Biologique et la Chronothérapie
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Biocompatibles International plc
British Columbia Cancer Agency
Cantonal Hospital of St. Gallen
Case Western Reserve University
Chao Family Comprehensive Cancer Center
Chinese University of Hong Kong
Chongqing Precision Biotech Co., Ltd
City of Hope National Medical Center
Clinica Universidad de Navarra
Eastern Cooperative Oncology Group
Gruppo Oncologico del Nord-Ovest
Holy Name Medical Center, Teaneck, NJ
Icahn School of Medicine at Mount Sinai
Medical University of South Carolina
Medizinische Hochschule Hannover
National Center for Research Resources (NCRR)
North Central Cancer Treatment Group
Northern Institute for Cancer Research Newcastle
Oregon Health and Science University
People's Liberation Army of China
Shanghai Cell Therapy Research Institute
Shanghai Junshi Bioscience Co.,Ltd.
Shenzhen Hank Bioengineering Institute
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
Technical University of Dresden
The University of Texas, Dallas
Université catholique de Louvain
University of California, Davis
University of California, Irvine
Organization Involved with Phase 1 Indications (55)
Methodist Cancer Center, Houston, Texas
National Comprehensive Cancer Network
Organization Involved with Other Experimental Indications (17)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
